Maintenance Pembrolizumab at Usual or Low doSE in non-squamous lung cancer: a non-inferiority study
2021/3336
Phase 3 other active
Quick answer
Maintenance Pembrolizumab at Usual or Low doSE in non-squamous lung cancer: a non-inferiority study for Maintenance treatment in metastatic non-squamous lung cancer is a Phase 3 program (other) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Institut für biomedizinische Analytik NMR-Imaging GmbH
- Indication
- Maintenance treatment in metastatic non-squamous lung cancer
- Phase
- Phase 3
- Modality
- other
- Status
- active